Zacks Research Has Optimistic Outlook of PBH Q4 Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Zacks Research upped their Q4 2025 earnings estimates for Prestige Consumer Healthcare in a research report issued on Thursday, November 28th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $1.28 per share for the quarter, up from their prior forecast of $1.24. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.44 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s Q2 2026 earnings at $1.19 EPS, Q3 2026 earnings at $1.25 EPS, FY2026 earnings at $4.74 EPS and FY2027 earnings at $4.96 EPS.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.09. The business had revenue of $283.79 million during the quarter, compared to analyst estimates of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. Prestige Consumer Healthcare’s quarterly revenue was down .9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.07 EPS.

PBH has been the subject of several other reports. Jefferies Financial Group restated a “hold” rating and issued a $76.00 target price (up from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. DA Davidson reaffirmed a “buy” rating and set a $95.00 price objective on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. One equities research analyst has rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Prestige Consumer Healthcare presently has an average rating of “Moderate Buy” and a consensus price target of $83.67.

Prestige Consumer Healthcare Price Performance

Shares of NYSE:PBH opened at $84.99 on Monday. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10. The stock has a market capitalization of $4.20 billion, a P/E ratio of 20.68, a P/E/G ratio of 2.38 and a beta of 0.47. The business has a 50-day moving average of $75.66 and a two-hundred day moving average of $71.34. Prestige Consumer Healthcare has a fifty-two week low of $57.95 and a fifty-two week high of $86.36.

Institutional Trading of Prestige Consumer Healthcare

Several institutional investors have recently modified their holdings of the company. Franklin Resources Inc. raised its stake in shares of Prestige Consumer Healthcare by 4.3% in the third quarter. Franklin Resources Inc. now owns 21,585 shares of the company’s stock valued at $1,513,000 after purchasing an additional 894 shares in the last quarter. Sanctuary Advisors LLC increased its holdings in Prestige Consumer Healthcare by 11.0% in the 3rd quarter. Sanctuary Advisors LLC now owns 17,248 shares of the company’s stock valued at $1,244,000 after buying an additional 1,715 shares during the period. Coldstream Capital Management Inc. acquired a new position in shares of Prestige Consumer Healthcare in the 3rd quarter valued at $205,000. Geode Capital Management LLC lifted its holdings in shares of Prestige Consumer Healthcare by 4.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock worth $95,678,000 after acquiring an additional 50,961 shares during the period. Finally, M&T Bank Corp boosted its position in shares of Prestige Consumer Healthcare by 23.8% during the 3rd quarter. M&T Bank Corp now owns 4,594 shares of the company’s stock valued at $331,000 after acquiring an additional 882 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Insider Buying and Selling at Prestige Consumer Healthcare

In related news, EVP Adel Mekhail sold 9,063 shares of the stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total value of $743,166.00. Following the completion of the sale, the executive vice president now owns 18,365 shares in the company, valued at approximately $1,505,930. This trade represents a 33.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Ronald M. Lombardi sold 10,875 shares of Prestige Consumer Healthcare stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total value of $898,275.00. Following the sale, the chief executive officer now directly owns 320,952 shares in the company, valued at approximately $26,510,635.20. This trade represents a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 38,810 shares of company stock valued at $3,187,300 in the last 90 days. 1.60% of the stock is currently owned by insiders.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.